Form 4: Director Douglas Ingram Receives Relay Therapeutics Options

Relay Therapeutics director Douglas S. Ingram was granted 32,947 stock options as part of standard equity compensation.

Summary

• Director Douglas S. Ingram received a grant of 32,947 stock options on June 9, 2026.
• The options have an exercise price of $14.09 per share.
• The options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual stockholders meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on company operations or financial health.

Positives

• Equity grant aligns director interests with long-term shareholder value.

Negatives

• Grant results in potential future dilution for existing shareholders.

Risks

• Market volatility could impact the value of the granted options relative to the exercise price.

Future Outlook

The options vest in full on the earlier of June 9, 2027, or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board alignment with corporate performance and long-term strategic goals.

Comparison to Industry Standards

• The grant structure follows standard industry practices for director compensation in mid-cap biotech firms.
• Vesting schedules tied to annual meetings are common governance practices to ensure director retention through the annual cycle.

Stakeholder Impact

• Minor dilution impact for existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on the earlier of June 9, 2027, or the next annual meeting.

Key Dates

Keywords

Relay Therapeutics, RLAY, Form 4, Insider Trading, Stock Options, Director Compensation